Lecture Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Algorithms for the Treatment of Metastatic Breast Cancer: Current Data on and Implications for New Trials in Early-Stage Breast Cancer

Release Date: October 31, 2008| Expiration Date: October 31, 2009
Oct 3, 2008, New York, NY

Lecture Overview

With an increasing number of treatment options for metastatic breast cancer, physicians are faced with the challenge of understanding which options might be best for individual patients. The Algorithms for the Treatment of Metastatic Breast Cancer: Current Data on and Implications for New Trials in Early-Stage Breast Cancer symposium is designed to educate physicians about recent data on the treatment of patients with breast cancer who might be facing more challenging clinical situations, including prior exposure to common cytotoxic agents such as taxanes, anthracyclines, and/or antimetabolites; disease that is both hormone receptor and HER2 negative; and disease that has relapsed after prior HER2-targeted therapy. This symposium will also describe the implications of recent data on epothilones and novel taxanes for ongoing and planned trials in patients with early-stage breast cancer.

This educational program is directed toward physicians with an interest in the treatment of breast cancer. Nurses, physician assistants, and other individuals interested in the treatment of breast cancer are also invited to participate.

At the conclusion of this activity, you should be able to:

  • Describe the role of novel taxane formulations and epothilones in the treatment algorithm for metastatic breast cancer within the context of specific patient scenarios and breast cancer subtypes
  • Discuss ongoing trials of and the clinical rationale for the integration of novel taxanes and epothilones into the treatment of early-stage breast cancer

Instructions for Participation

  1. Read the following information before beginning the educational activity.
  2. Complete the Pretest.
  3. View and study all Flash video presentations.
  4. Complete the CME test.
  5. Answer the evaluation questions.
  6. After successful completion of the CME test and evaluation, you will receive your certificate online.
  • CME credit will be granted for online participation only.

Read all of the conditions in the Activity Terms box below. You must accept the Activity Terms in order to continue:

Disclosure Policy

It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

These persons involved in the influence or control of content for the presentations from the Algorithms for the Treatment of Metastatic Breast Cancer: Current Data on and Implications for New Trials in Early-Stage Breast Cancer symposium have disclosed the following relationship with the companies listed. The PER Scientific Content Team has no relevant financial relationships to disclose, unless noted below individually.

Joyce O’Shaughnessy
Paid Consultant/Advisory Board – AstraZeneca; Eisai Inc.; Eli Lilly and Company; Genentech, Inc.; Molecular Profiling Institute; Novartis Pharmaceuticals Corporation; Pfizer Inc.; sanofi-aventis U.S.
Speaker’s Bureau – Abraxis Bioscience, LLC; AstraZeneca; Eli Lilly and Company; sanofi-aventis U.S.

Edward Romond
Paid Consultant/Advisory Board – Genentech, Inc.

Joseph A. Sparano
Research Funding – Bristol-Myers Squibb Company; Genentech, Inc.; GlaxoSmithKline
Paid Consultant – Bristol-Myers Squibb; Eisai Inc.; Eli Lilly and Company; Genentech, Inc.; GlaxoSmithKline; Johnson & Johnson; sanofi-aventis U.S.
Speaker’s Bureau – Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation

Software Requirements

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your Web browser, follow one of the links listed below:

Macintosh Users
Compatible Web browsers include

Disclaimer

The views and opinions expressed in this learning activity are those of the presenters and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the presenters and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is delineated by the faculty during the presentation. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

Privacy Policy

Physicians' Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

©Copyright 2008 by Physicians’ Education Resource.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

All correspondence should be directed to:
Editor, Algorithms for the Treatment of Metastatic Breast Cancer: Current Data on and Implications for New Trials in Early-Stage Breast Cancer
Physicians' Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3400
Fax: (214) 367-3304
E-mail: editor@pergrouplp.com

Educational Grants

An educational grant for this activity was provided by:


  1. Bristol-Myers Squibb